These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35845129)

  • 21. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
    Sun SS; Guo XD; Li WD; Chen JL
    World J Clin Cases; 2024 Jan; 12(2):285-292. PubMed ID: 38313649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
    Front Oncol; 2021; 11():783480. PubMed ID: 34988019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Guo W; Chen S; Wu Z; Zhuang W; Yang J
    Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium.
    Ning S; Li X; Ma X; Liu J; Chang X
    J Hepatocell Carcinoma; 2023; 10():1511-1525. PubMed ID: 37724186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma.
    Wu J; Zeng J; Wang H; Huo Z; Hou X; He D
    Front Oncol; 2023; 13():1244341. PubMed ID: 37916160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.
    Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Yang M; Wu XN
    Integr Cancer Ther; 2018 Jun; 17(2):477-485. PubMed ID: 29108428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
    Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
    Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Elsayed ZA
    Dig Dis Sci; 2013 Dec; 58(12):3389-96. PubMed ID: 24046163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of transcatheter arterial chemoembolization combined with 125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma.
    Zhang H; Yang A; Zhang J
    J BUON; 2020; 25(2):952-958. PubMed ID: 32521891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.